abstract |
The present invention relates to HMG-Co-A reductase inhibitors, in particular fluvastatin or pitavastatin or pharmaceutically acceptable salts and mTOR inhibitors thereof, for example rapamycin or rapamycin derivatives. It relates to a pharmaceutical formulation comprising. |